

# Kylie E C Ainslie

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/200544/publications.pdf>

Version: 2024-02-01

34  
papers

5,964  
citations

430874

18  
h-index

501196

28  
g-index

63  
all docs

63  
docs citations

63  
times ranked

10140  
citing authors

#	ARTICLE	IF	CITATIONS
1	SARS-CoV-2 infection and vaccine effectiveness in England (REACT-1): a series of cross-sectional random community surveys. <i>Lancet Respiratory Medicine</i> , 2022, 10, 355-366.	10.7	39
2	Is annual vaccination best? A modelling study of influenza vaccination strategies in children. <i>Vaccine</i> , 2022, 40, 2940-2948.	3.8	1
3	Database of epidemic trends and control measures during the first wave of COVID-19 in mainland China. <i>International Journal of Infectious Diseases</i> , 2021, 102, 463-471.	3.3	12
4	SARS-CoV-2 antibody prevalence in England following the first peak of the pandemic. <i>Nature Communications</i> , 2021, 12, 905.	12.8	168
5	Reduction in mobility and COVID-19 transmission. <i>Nature Communications</i> , 2021, 12, 1090.	12.8	394
6	Resurgence of SARS-CoV-2: Detection by community viral surveillance. <i>Science</i> , 2021, 372, 990-995.	12.6	91
7	Prevalence of antibody positivity to SARS-CoV-2 following the first peak of infection in England: Serial cross-sectional studies of 365,000 adults. <i>Lancet Regional Health - Europe</i> , The, 2021, 4, 100098.	5.6	91
8	Comparing statistical methods for detecting and estimating waning efficacy of rotavirus vaccines in developing countries. <i>Human Vaccines and Immunotherapeutics</i> , 2021, 17, 4632-4635.	3.3	2
9	Exponential growth, high prevalence of SARS-CoV-2, and vaccine effectiveness associated with the Delta variant. <i>Science</i> , 2021, 374, eabl9551.	12.6	111
10	Optimal vaccine allocation for COVID-19 in the Netherlands: A data-driven prioritization. <i>PLoS Computational Biology</i> , 2021, 17, e1009697.	3.2	16
11	Potential impact of the COVID-19 pandemic on HIV, tuberculosis, and malaria in low-income and middle-income countries: a modelling study. <i>The Lancet Global Health</i> , 2020, 8, e1132-e1141.	6.3	573
12	State-level tracking of COVID-19 in the United States. <i>Nature Communications</i> , 2020, 11, 6189.	12.8	104
13	Response to COVID-19 in South Korea and implications for lifting stringent interventions. <i>BMC Medicine</i> , 2020, 18, 321.	5.5	137
14	SARS-CoV-2 infection prevalence on repatriation flights from Wuhan City, China. <i>Journal of Travel Medicine</i> , 2020, 27, .	3.0	5
15	Comparison of molecular testing strategies for COVID-19 control: a mathematical modelling study. <i>Lancet Infectious Diseases</i> , The, 2020, 20, 1381-1389.	9.1	171
16	An open source tool to infer epidemiological and immunological dynamics from serological data: sersolver. <i>PLoS Computational Biology</i> , 2020, 16, e1007840.	3.2	13
17	The impact of COVID-19 and strategies for mitigation and suppression in low- and middle-income countries. <i>Science</i> , 2020, 369, 413-422.	12.6	718
18	Estimating the effects of non-pharmaceutical interventions on COVID-19 in Europe. <i>Nature</i> , 2020, 584, 257-261.	27.8	2,558

#	ARTICLE	IF	CITATIONS
19	Evidence of initial success for China exiting COVID-19 social distancing policy after achieving containment. Wellcome Open Research, 2020, 5, 81.	1.8	62
20	Evidence of initial success for China exiting COVID-19 social distancing policy after achieving containment. Wellcome Open Research, 2020, 5, 81.	1.8	81
21	Anonymised and aggregated crowd level mobility data from mobile phones suggests that initial compliance with COVID-19 social distancing interventions was high and geographically consistent across the UK. Wellcome Open Research, 2020, 5, 170.	1.8	58
22	Title is missing!. , 2020, 16, e1007840.		0
23	Title is missing!. , 2020, 16, e1007840.		0
24	Title is missing!. , 2020, 16, e1007840.		0
25	Title is missing!. , 2020, 16, e1007840.		0
26	Title is missing!. , 2020, 16, e1007840.		0
27	Challenges in estimating influenza vaccine effectiveness. Expert Review of Vaccines, 2019, 18, 615-628.	4.4	46
28	Bias of influenza vaccine effectiveness estimates from test-negative studies conducted during an influenza pandemic. Vaccine, 2019, 37, 1987-1993.	3.8	10
29	A Dynamic Model for Evaluation of the Bias of Influenza Vaccine Effectiveness Estimates From Observational Studies. American Journal of Epidemiology, 2019, 188, 451-460.	3.4	3
30	Maximum likelihood estimation of influenza vaccine effectiveness against transmission from the household and from the community. Statistics in Medicine, 2018, 37, 970-982.	1.6	9
31	On the bias of estimates of influenza vaccine effectiveness from test-negative studies. Vaccine, 2017, 35, 7297-7301.	3.8	31
32	A comparison of the test-negative and the traditional case-control study designs for estimation of influenza vaccine effectiveness under nonrandom vaccination. BMC Infectious Diseases, 2017, 17, 757.	2.9	33
33	Gene integrated set profile analysis: a context-based approach for inferring biological endpoints. Nucleic Acids Research, 2016, 44, e69-e69.	14.5	11
34	Characterising the persistence of RT-PCR positivity and incidence in a community survey of SARS-CoV-2. Wellcome Open Research, 0, 7, 102.	1.8	7